Optimi Health Corp operates in developing a vertically integrated Canadian functional mushroom brand that focuses on the health and wellness sector... Show more
A.I.dvisor tells us that OPTH and GELS have been poorly correlated (+8% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that OPTH and GELS's prices will move in lockstep.
| Ticker / NAME | Correlation To OPTH | 1D Price Change % | ||
|---|---|---|---|---|
| OPTH | 100% | -9.80% | ||
| GELS - OPTH | 8% Poorly correlated | -6.12% | ||
| GLAS - OPTH | 6% Poorly correlated | +2.60% | ||
| AKAN - OPTH | 4% Poorly correlated | -8.85% | ||
| HLN - OPTH | 3% Poorly correlated | +1.00% | ||
| ALVO - OPTH | 3% Poorly correlated | +4.05% | ||
More | ||||
Industry PharmaceuticalsGeneric
The RSI Oscillator for OPTH moved into overbought territory on November 10, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 66 cases where OPTH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for OPTH just turned positive on November 10, 2026. Looking at past instances where OPTH's MACD turned positive, the stock continued to rise in 42 of 56 cases over the following month. The odds of a continued upward trend are 75%.
Following a +13.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where OPTH advanced for three days, in 172 of 201 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
OPTH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OPTH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for OPTH entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.760) is normal, around the industry mean (6.379). P/E Ratio (-1.164) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (135.135) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. OPTH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 70 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OPTH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.